Lyra Therapeutics
Clinical-stage biotechnology company developing implantable, bioabsorbable drug-delivery matrices to provide sustained local anti-inflammatory therapy for chronic rhinosinusitis (CRS). The organization combines materials science, drug formulation and clinical development to deliver medicines directly to sinonasal tissues via brief in-office procedures and has advanced product candidates through preclinical studies and multiple clinical phases.
Industries
Nr. of Employees
medium (51-250)
Lyra Therapeutics
Patents
Implantable scaffolds for treatment of sinusitis and method of reducing inflammation
US-11654213-B2
View Details
Implantable scaffolds for treatment of sinusitis and method of reducing inflammation
US-11654213-B2
View DetailsProducts
LYR-210
A bioabsorbable nasal mesh implant designed to deliver up to six months of continuous local corticosteroid therapy to sinonasal tissues via a brief in-office placement; developed for patients with chronic rhinosinusitis who have not had prior sinus surgery.
LYR-220
A bioresorbable implant matrix formulated to expand and line post-surgical sinonasal anatomy to deliver sustained local corticosteroid therapy for up to six months; developed for CRS patients with prior sinus surgery.
XTreo
Proprietary technology platform designed to deliver medicines precisely and consistently to the affected tissue for sustained periods with a single administration for chronic rhinosinusitis.
LYR-210
A bioabsorbable nasal mesh implant designed to deliver up to six months of continuous local corticosteroid therapy to sinonasal tissues via a brief in-office placement; developed for patients with chronic rhinosinusitis who have not had prior sinus surgery.
LYR-220
A bioresorbable implant matrix formulated to expand and line post-surgical sinonasal anatomy to deliver sustained local corticosteroid therapy for up to six months; developed for CRS patients with prior sinus surgery.
XTreo
Proprietary technology platform designed to deliver medicines precisely and consistently to the affected tissue for sustained periods with a single administration for chronic rhinosinusitis.
Expertise Areas
- Implantable drug-delivery development
- Materials science for bioresorbable implants
- Clinical trial management for combination products
- Pharmacokinetics and PK analysis
Key Technologies
- Bioresorbable polymer scaffolds
- Implantable drug-eluting mesh
- Elastomeric adaptive matrices
- Controlled-release polymer–drug formulations
News & Updates
Corporate update published by the company.
Quarterly financial results and corporate update.
Announcement of Phase 3 clinical plan for the lead implant program and late-breaking oral presentation of Phase 3 study.
Peer-reviewed publication reporting results from a randomized Phase 2 study evaluating a long-acting implantable corticosteroid matrix in CRS.
Publication reporting quality-of-life outcomes from the LANTERN randomized study.
PK study demonstrating steady and sustained release from implantable corticosteroid matrices.
Corporate update published by the company.
Quarterly financial results and corporate update.
Announcement of Phase 3 clinical plan for the lead implant program and late-breaking oral presentation of Phase 3 study.
Peer-reviewed publication reporting results from a randomized Phase 2 study evaluating a long-acting implantable corticosteroid matrix in CRS.
Publication reporting quality-of-life outcomes from the LANTERN randomized study.
PK study demonstrating steady and sustained release from implantable corticosteroid matrices.